Stock info Regulus Therapeutics Inc | Filter  Basic-Info

Regulus Therapeutics Inc

The past year was a relatively good year for Regulus Therapeutics Inc investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Regulus Therapeutics Inc. The stock lost around 73 percent. Over the past 5 years Regulus Therapeutics Inc' stock lost at around 0 percent in value. Regulus Therapeutics Inc's revenues between 2011 and 2015 were quite unstable and moved between 12,7 million dollars and 20,76 million dollars. Regulus Therapeutics Inc's net results between 2011 and 2015 were quite unstable and moved between -7,6 million dollars and -55,75 million dollars.

Regulus Therapeutics Inc is mostly active in the biotech sector. The global biotech companies gained around 59 percent worldwide over the last 10 years. Since 2011 the sector is 70 percent higher and over the past year minus 59 percent.

The American company didn't pay out any dividends (in the past 5 years).

Quite a lot of debt Regulus Therapeutics Inc

At the end of 2015 the American company's balance sheet was worth 141,08 million dollars. 17 million dollars (12,05 percent of the total balance sheet) was financed by debt. The American company's price/earnings-ratio was -15. So the market valued the stock at -15 times the 2015' earnings per share. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 440,6 million dollars. At the end of 2015 the American company had around 51,41 million stocks listed.

All the company's financial reports are available here. More information about Regulus Therapeutics Inc can be found it's website. .